The Effect of Autologous Hematopoietic Stem Cell Transplantation on the Lower Urinary Tract Function Related to QoL in MS Patients

Inclusion criteria

• Subjects (male and female) aged 18 and over
• Subjects with signed informed consent
• Subjects able to undergo examination according to the protocol
• Patients indicated by neurologists to perform AHSCT or treated with the closest similar disease-modifying therapy (control group)

Exclusion criteria

• Subjects with a history of bladder cancer
• Subjects after previous pelvic radiotherapy
• Subjects with evidence of microscopic or macroscopic hematuria
• Subjects with a history of bladder reconstruction (augmentation cystoplasty, catheterizable stoma), subjects after cystectomy
• Treatment with botulinum toxin injection into the bladder wall in the last 12 months
• Patients in whom the pharmacological treatment of the lower urinary tract has not been stable in the last 3 months and is being adjusted
• Patients whose lower urinary tract symptoms are not stable for at least 3 months
• Patients with a permanent catheter
• Patients with recurrent symptomatic lower urinary tract infections - 3 or more episodes of infection in the last 12 months
• Subjects with tubal urine screening-proven bacteriuria
• Patients with acute lower urinary tract inflammation at baseline
• Subjects with painful bladder syndrome
• Patients after sacral neuromodulation
• Patients with severe pelvic organ prolapse
• Patients after radical pelvic surgery
• Patients with a life expectancy of less than 5 years at the time of inclusion in the study
• Lactating women, pregnant women, women trying to get pregnant, or sexually active women without a tendency to use safe contraception (hormonal-based oral contraceptives, injectable contraception, hormonally active implants, sexual abstinence, vasectomy in a partner)
• Subjects who participated in another study in the previous 90 days